CA19-9 Cancer Antigen (High Purity)
| Catalog number: | B2012290 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 10 kU |
| Molecular Weight or Concentration: | NA |
| Supplied as: | Liquid |
| Applications: | molecular tool for various biochemical applications |
| Storage: | -20C |
| Keywords: | CA19-9 |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Scar S, Bottoni P, Scatena R. CA 19-9: Biochemical and Clinical Aspects Adv Exp Med Biol. 2015;867:247-60.
- Rao H, Wu H, Huang Q, Yu Z, Zhong Z. Clinical Value of Serum CEA, CA24-2 and CA19-9 in Patients with Colorectal Cancer Clin Lab. 2021 Apr 1;67(4).
- Lertkhachonsuk AA, Buranawongtrakoon S, Lekskul N, Rermluk N, Wee-Stekly WW, Charakorn C. Serum CA19-9, CA-125 and CEA as tumor markers for mucinous ovarian tumors J Obstet Gynaecol Res. 2020 Nov;46(11):2287-2291.
- Moriyama J, Oshima Y, Nanami T, Suzuki T, Yajima S, Shiratori F, Funahashi K, Shimada H. Prognostic impact of CEA/CA19-9 at the time of recurrence in patients with gastric cancer Surg Today. 2021 Oct;51(10):1638-1648.
- Haring MPD, de Cort BA, Nieuwenhuijs VB. [Elevated CA19-9 levels; not always cancer] Ned Tijdschr Geneeskd. 2021 Mar 2;164:D4048.
- Pavai S, Yap SF. The clinical significance of elevated levels of serum CA 19-9 Med J Malaysia. 2003 Dec;58(5):667-72.
- Kim HS, Han Y, Kang JS, Kang YH, Lee M, Sohn HJ, Kim H, Kwon W, Jang JY. Serum carcinoembryonic antigen and carbohydrate antigen 19-9 as preoperative diagnostic biomarkers of extrahepatic bile duct cancer BJS Open. 2021 Nov 9;5(6):zrab127.
- Liu JM, Wang YY, Liu W, Xu D, Wang K, Xing BC. Preoperative CA19-9: a competitive predictor of recurrence in patients with colorectal cancer liver metastases after hepatectomy Int J Colorectal Dis. 2021 Apr;36(4):767-778.
- Odagiri E. [CA19-9] Nihon Rinsho. 2005 Aug;63 Suppl 8:642-4.
